These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 7895956)

  • 1. Alterations in apolipoprotein B-48 in the postprandial state in NIDDM.
    Curtin A; Deegan P; Owens D; Collins P; Johnson A; Tomkin GH
    Diabetologia; 1994 Dec; 37(12):1259-64. PubMed ID: 7895956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intestinally derived lipoprotein particles in non-insulin-dependent diabetic patients with and without hypertriglyceridaemia.
    Curtin A; Deegan P; Owens D; Collins P; Johnson A; Tomkin GH
    Acta Diabetol; 1995 Dec; 32(4):244-50. PubMed ID: 8750763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of dietary cholesterol in the regulation of postprandial apolipoprotein B48 levels in diabetes.
    Taggart C; Gibney J; Owens D; Collins P; Johnson A; Tomkin GH
    Diabet Med; 1997 Dec; 14(12):1051-8. PubMed ID: 9455933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated triglyceride-rich lipoproteins in diabetes. A study of apolipoprotein B-48.
    Curtin A; Deegan P; Owens D; Collins P; Johnson A; Tomkin GH
    Acta Diabetol; 1996 Sep; 33(3):205-10. PubMed ID: 8904926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postprandial apolipoprotein B48-and B100-containing lipoproteins in type 2 diabetes: do statins have a specific effect on triglyceride metabolism?
    Battula SB; Fitzsimons O; Moreno S; Owens D; Collins P; Johnson A; Tomkin GH
    Metabolism; 2000 Aug; 49(8):1049-54. PubMed ID: 10954025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved metabolic control reduces the number of postprandial apolipoprotein B-48-containing particles in type 2 diabetes.
    Phillips C; Murugasu G; Owens D; Collins P; Johnson A; Tomkin GH
    Atherosclerosis; 2000 Feb; 148(2):283-91. PubMed ID: 10657563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma apolipoprotein changes in the triglyceride-rich lipoprotein fraction of human subjects fed a fat-rich meal.
    Cohn JS; McNamara JR; Cohn SD; Ordovas JM; Schaefer EJ
    J Lipid Res; 1988 Jul; 29(7):925-36. PubMed ID: 3411251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early alterations in the postprandial VLDL1 apoB-100 and apoB-48 metabolism in men with strong heredity for type 2 diabetes.
    Johanson EH; Jansson PA; Gustafson B; Lönn L; Smith U; Taskinen MR; Axelsen M
    J Intern Med; 2004 Feb; 255(2):273-9. PubMed ID: 14746565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in postprandial lipemia between patients with normal glucose tolerance and noninsulin-dependent diabetes mellitus.
    Chen YD; Swami S; Skowronski R; Coulston A; Reaven GM
    J Clin Endocrinol Metab; 1993 Jan; 76(1):172-7. PubMed ID: 8421086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM.
    Cummings MH; Watts GF; Umpleby AM; Hennessy TR; Naoumova R; Slavin BM; Thompson GR; Sönksen PH
    Diabetologia; 1995 Aug; 38(8):959-67. PubMed ID: 7589883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postprandial triglyceride-rich lipoprotein metabolism and insulin sensitivity in nonalcoholic steatohepatitis patients.
    Cassader M; Gambino R; Musso G; Depetris N; Mecca F; Cavallo-Perin P; Pacini G; Rizzetto M; Pagano G
    Lipids; 2001 Oct; 36(10):1117-24. PubMed ID: 11768156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postprandial changes in the distribution of apolipoprotein AIV between apolipoprotein B- and non apolipoprotein B-containing lipoproteins in obese women.
    Ferrer F; Nazih H; Zaïr Y; Krempf M; Bard JM
    Metabolism; 2003 Dec; 52(12):1537-41. PubMed ID: 14669151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postprandial metabolism of apolipoprotein B-48- and B-100-containing particles in type 2 diabetes mellitus: relations to angiographically verified severity of coronary artery disease.
    Mero N; Malmström R; Steiner G; Taskinen MR; Syvänne M
    Atherosclerosis; 2000 May; 150(1):167-77. PubMed ID: 10781648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed clearance of postprandial large TG-rich particles in normolipidemic carriers of LPL Asn291Ser gene variant.
    Mero N; Suurinkeroinen L; Syvänne M; Knudsen P; Yki-Järvinen H; Taskinen MR
    J Lipid Res; 1999 Sep; 40(9):1663-70. PubMed ID: 10484613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects.
    Taskinen MR; Björnson E; Andersson L; Kahri J; Porthan K; Matikainen N; Söderlund S; Pietiläinen K; Hakkarainen A; Lundbom N; Nilsson R; Ståhlman M; Adiels M; Parini P; Packard C; Borén J
    J Clin Lipidol; 2020; 14(1):77-87. PubMed ID: 31917184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postprandial lipid metabolism and beta-cell function in non-insulin-dependent (type 2) diabetes mellitus after a mixed meal with a high fat content.
    Cooper MB; Tan KC; Hales CN; Betteridge DJ
    Diabet Med; 1996 Sep; 13(9):816-27. PubMed ID: 8891457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postprandial lipoprotein metabolism in normotriglyceridemic non-insulin-dependent diabetic patients: influence of apolipoprotein E polymorphism.
    Reznik Y; Pousse P; Herrou M; Morello R; Mahoudeau J; Drosdowsky MA; Fradin S
    Metabolism; 1996 Jan; 45(1):63-71. PubMed ID: 8544779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.
    Matikainen N; Mänttäri S; Schweizer A; Ulvestad A; Mills D; Dunning BE; Foley JE; Taskinen MR
    Diabetologia; 2006 Sep; 49(9):2049-57. PubMed ID: 16816950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postprandial thrombin activatable fibrinolysis inhibitor and markers of endothelial dysfunction in type 2 diabetic patients.
    Rigla M; Wägner AM; Borrell M; Mateo J; Foncuberta J; de Leiva A; Ordóñez-Llanos J; Pérez A
    Metabolism; 2006 Nov; 55(11):1437-42. PubMed ID: 17046544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum lipids and lipoprotein(a) concentrations in Chinese NIDDM patients. Relation to metabolic control.
    Chang CJ; Kao JT; Wu TJ; Lu FH; Tai TY
    Diabetes Care; 1995 Aug; 18(8):1191-4. PubMed ID: 7587858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.